Half of older U.S. adults take aspirin as preventive medicine
the ONA take:
A survey of more than 2,500 older US adults revealed that 52% of those ages 45 to 75 years use aspirin, and another 21% had used it at some point in the past, even though the FDA does not recommend its use for most people who have not had a heart attack or stroke.
In this study, 81% of older adults using aspirin have not had a heart attack or stroke and take it as primary prevention.
Caution is advised because aspirin is a blood thinner and cause bleeding events. According to the FDA, for every first heart attack or stroke that is prevented by taking aspirin, there is approximately one major bleeding event, such as GI bleeding, that is caused by the practice.
The US Preventive Services Task Force, however, says aspirin use may be appropriate for patients at higher risk for cardiovascular events, such as those with high blood pressure, high cholesterol, or diabetes, and those who smoke.
The survey also showed that many patients who take aspirin have discussed it with their doctors, and are aware of the risks.
The reasons cited for aspirin use included to prevent heart attack (84%), stroke (66%), cancer (18%), and Alzheimer disease (11%).
52% of those ages 45 to 75 years use aspirin, and another 21% had used it at some point in the past.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|